Oramed Pharmaceuticals Inc.
DE ˙ DB ˙ US68403P2039
3,24 € ↓ -0,02 (-0,77%)
2026-06-05
DEL PRIS
SecurityDE:OJU1 / Oramed Pharmaceuticals Inc.
InstitutionRathbone Brothers plc
Latest Disclosed Ownership233,018 shares
Latest Disclosed Value $ 792,261
Rathbone Brothers plc ownership in OJU1 / Oramed Pharmaceuticals Inc.

On May 12, 2026 - Rathbone Brothers plc filed a 13F-HR form disclosing ownership of 233,018 shares of Oramed Pharmaceuticals Inc. (DE:OJU1) valued at $658,276 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 6, 2026 disclosing 233,018 shares of Oramed Pharmaceuticals Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $754,978 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ORAMED PHARMACEUTICALS INC USD0.001 COM 68403P203 233,018 0 0.00 792 19.28 0.0034
2026-02-06 2025-12-31 13F/A-1 ORAMED PHARMACEUTICALS INC USD0.001 COM 68403P203 233,018 0 0.00 664 7.97 0.0026
2026-01-21 2025-12-31 13F ORAMED PHARMACEUTICALS INC USD0.001 COM 68403P203 233,018 0 664 0.0026
2025-11-13 2025-09-30 13F ORAMED PHARMACEUTICALS INC USD0.001 COM 68403P203 233,018 0 0.00 615 17.37 0.0025
2025-08-07 2025-06-30 13F ORAMED PHARMACEUTICALS INC USD0.001 COM 68403P203 233,018 -3,785 -1.60 524 3.56 0.0023
2025-05-13 2025-03-31 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 236,803 -53,000 -18.29 507 -27.82 0.0024
2025-02-13 2024-12-31 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 0 0.00 701 -0.85 0.0034
2024-11-13 2024-09-30 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 0 0.00 707 -4.97 0.0036
2024-08-09 2024-06-30 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 0 0.00 745 -12.06 0.0041
2024-05-14 2024-03-31 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 0 0.00 846 26.46 0.0049
2024-02-13 2023-12-31 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 0 0.00 669 -11.51 0.0043
2023-11-13 2023-09-30 13F Oramed Pharma Inc COM USD0.001 COM 68403P203 289,803 289,803 756 0.0055
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.